General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FOJKK
ADC Name
Bevacizumab-DOX-PDT-2
Synonyms
Bevacizumab-DOX-PDT-2; ADC 2
   Click to Show/Hide
Organization
Xi'an Jiaotong University.
Drug Status
Investigative
Structure
Antibody Name
Bevacizumab
 Antibody Info 
Antigen Name
Vascular endothelial growth factor A (VEGFA)
 Antigen Info 
Payload Name
Doxorubicin
 Payload Info 
Payload Name
PDT
 Payload Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.2428&#1770.3175
ug/mL
CVCL_0027
Hepatoblastoma
Half Maximal inhibitory Concentration (lC50) 
2.028&#1770.4680
ug/mL
CVCL_0320
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
2.061&#1770.2655
ug/mL
CVCL_0023
Lung adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
3.135&#1770.2752
ug/mL
CVCL_0027
Hepatoblastoma
Half Maximal inhibitory Concentration (lC50) 
3.908&#1770.3628
ug/mL
CVCL_0320
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
7.437&#1770.2055
ug/mL
CVCL_0023
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.2428&#1770.3175 ug/mL Positive VEGFA expression ( VEGFA+++/++)
Method Description
In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

   Click to Show/Hide
In Vitro Model Hepatoblastoma HepG2 cells (+hv) CVCL_0027
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 2.028&#1770.4680 ug/mL Positive VEGFA expression ( VEGFA+++/++)
Method Description
In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma HT-29 cells (+hv) CVCL_0320
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 2.061&#1770.2655 ug/mL Positive VEGFA expression ( VEGFA+++/++)
Method Description
In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma A549 cells (+hv) CVCL_0023
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 3.135&#1770.2752 ug/mL Positive VEGFA expression ( VEGFA+++/++)
Method Description
In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

   Click to Show/Hide
In Vitro Model Hepatoblastoma HepG2 cells (-hv) CVCL_0027
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 3.908&#1770.3628 ug/mL Positive VEGFA expression ( VEGFA+++/++)
Method Description
In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma HT-29 cells (-hv) CVCL_0320
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 7.437&#1770.2055 ug/mL Positive VEGFA expression ( VEGFA+++/++)
Method Description
In vitro activity evaluation mainly included antitumor cell proliferation, apoptosis, cell cycle, anticell migration, and in vitro antiangiogenesis activity evaluation. In this study, HT-29, A549, and HepG2 cells were selected as experimental cell lines to evaluate the antitumor activity in vitro. The antiproliferative activity of ADC was evaluated based on the CCK-8 method, with the concentration range set to 0-10 ug/mL, and the illumination time set to 15 min. Annexin V-FITC/PI double staining and technique. The concentration was 10 ug/mL at the initial screening, the concentration range was 0-20 ug/mL in a concentration-dependent setting, and the light time was 15 min. The cell cycle arrest activity was assessed using PI staining. The concentration was 5 ug/mL at the initial screening, the concentration range was 0-10 ug/mL in a concentration-dependent study, and the illumination time was 15 min. In the evaluation of anticell migration activity, the concentration of ADC was set to 10 ug/mL, and the illumination time was set to 15 min. The evaluation of antiangiogenesis activity in vitro included assessing the toxicity of ADC to HUVEC cells and evaluating anti-HUVEC cell migration activity. Cytotoxicity was evaluated using the CCK-8 method and the Ca-AM/PI method, respectively. In the evaluation of anti-HUVEC cell migration activity, the ADC concentration was set at 10 ug/mL.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma A549 cells (-hv) CVCL_0023
References
Ref 1 Discovery of a Novel ADC for Multifunctional Theranostics: From Vascular Normalization to Synergistic Therapy